← Leaderboards
Lorna Rodriguez-Rodriguez
Univ Of Med/Dent Nj-R W Johnson Med Sch
$2,866,039
Attributed
$4,258,969
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $723K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,258,969 · 2
By mechanism
R01$4,258,969 · 2
Top collaborators
- Saul Priceman4 shared
Most similar at Univ Of Med/Dent Nj-R W Johnson Med Sch
Same institution · by research overlap
- William N Hait$3,322,304
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMalignant Neoplasm Of OvarySiteFutureNeoplasm MetastasisProgramsPhenotypeCancer CellIn VivoMembrane ProteinsCancer BiologyLinkBreast Cancer CellCancer Cell LineGlycosaminoglycansHyaluronanCd44 AntigensAbcb1 GeneCd44 GeneCell AdhesionCell MembraneCell MotilityExtracellular MatrixDeletion Mutation
Grant awards (9)
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer$704,036
R01 · FY2025 · CA · contact PI
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer$668,834
R01 · FY2024 · CA · contact PI
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer$689,955
R01 · FY2023 · CA
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer$723,036
R01 · FY2022 · CA
Regulation of MDR1 Expression and Drug Resistance by CD44$287,508
R01 · FY2011 · CA · contact PI
Regulation of MDR1 Expression and Drug Resistance by CD44$296,400
R01 · FY2010 · CA · contact PI
Regulation of MDR1 Expression and Drug Resistance by CD44$296,400
R01 · FY2009 · CA · contact PI
Regulation of MDR1 Expression and Drug Resistance by CD44$296,400
R01 · FY2008 · CA · contact PI
Regulation of MDR1 Expression and Drug Resistance by CD44$296,400
R01 · FY2007 · CA · contact PI